Healthy volunteers needed to compare two HRS-1893 tablet forms
NCT ID NCT07479641
First seen Jun 25, 2026 · Last updated Sep 21, 2026 · Updated 6 times
Summary
This early-stage study will check if two different tablet forms of the drug HRS-1893 are processed the same way in the body. Thirty-six healthy adults will take both versions and have blood tests to measure drug levels. The goal is to see if the two formulations are equivalent, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- HRS-1893 tablet
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
58 people
The number who actually took part.
- Started
-
Apr 2026
- Finished
-
Sep 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Subjects aged 18 to 55 years (inclusive), regardless of gender; 2. Body mass index (BMI) between 19 and 28 kg/m² (inclusive), with body weight ≥ 50.0 kg and \< 90.0 kg for men, and ≥ 45.0 kg and \< 90.0 kg for women; 3. No abnormalities of clinical significance are found upon comprehensive physical examination and laboratory tests, or only minor abnormalities that are deemed by the investigator not to affect the subject's eligibility for enrollment; 4. No clinically significant abnormalities on the 12-lead ECG; 5. The subject must understand the study procedures and methods, voluntarily agree to participate, and provide written informed consent. Exclusion Criteria: 1. Subjects with suspected hypersensitivity to the investigational drug or any excipient; 2. The subject has a history of syncope; 3. Exclusion due to blood pressure: Systolic Blood Pressure (SBP) \>140 mmHg or \<90 mmHg; OR Diastolic Blood Pressure (DBP) \>90 mmHg or \<60 mmHg, as determined by the investigator to be clinically significant; 4. History of gastric or intestinal surgery that, in the investigator's judgment, may affect drug absorption; 5. A positive result in any one of the following infectious disease screening tests during the screening period: hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab), treponema pallidum antibody (syphilis), or human immunodeficiency virus antibody/antigen (HIV-Ab/Ag); 6. Subjects who meet any of the following criteria will be excluded: a. Smoking: Average daily cigarette consumption of more than 5 cigarettes within the 4 weeks prior to screening; b. Alcohol: Average daily alcohol intake exceeding 15 g within one week prior to screening (15 g of alcohol is equivalent to 450 mL of beer, 150 mL of wine, or 50 mL of low-alcohol spirits); c. Non-compliance: Inability or unwillingness to abstain from smoking, alcohol, and caffeine-containing foods or beverages during the screening period and the entire study duration; d. Diet: Have special dietary requirements, cannot comply with the standardized diet provided in the study, or have a history of substance abuse; 7. History of substance abuse; 8. Use of any prescription drugs, over-the-counter medications, or Chinese herbal medicines within 1 month prior to dosing, or the use of any drug within 5 half-lives prior to screening (whichever is longer). Additionally, subjects who plan to take any non-study medications during the trial period will be excluded; 9. Any other circumstances that, in the investigator's judgment, make the subject unsuitable for participation in the trial. This includes physiological or psychological conditions that may increase the trial risk, affect the subject's protocol compliance, or impact the subject's ability to complete the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cardiomyopathy are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Hospital
Beijing, Beijing Municipality, 100730, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Do genes drive heart damage from irregular rhythms?
- Can heart surgery rehab move from hospital to home?
- Can a gene registry unlock the secrets of childhood heart failure?
- Can a heart pump spark its own recovery? a new study investigates
- Implanted sensors may foresee heart failure crises
- Can a Gene-Silencing drug tame a rare heart disease?